ADDED
The number of shares of the registrant s common stock o utstanding as of February 20, 2026, was 56,331,110 .
These forward-looking statements are based on information available to us at the time of this Form 10-K and current operations, forecasts and assumptions and involve a number of judgments, risks and uncertainties.
We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs including monoclonal antibodies ( mAbs ) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies ( C GT ) that are improving human health worldwide.
A majority of our 19 manufacturing sites are located in the United States (including California, Massachusetts, New Hampshire, New Jersey and New York).
The majority of our revenue is derived from consumable and/or single-campaign ( single-use ) product sales, though we have grown our hardware and equipment offerings in recent years.
Shifting to Integrated Solutions Since 2012, we have completed 15 acquisitions across our four franchises, building a base of technology assets that we can improve upon and/or develop next-generation versions of through our internal R D team.
Our acquisition strategy focuses on differentiated technology, while considering the potential for integration with our internally-developed technologies, across products and franchises, and the financial impact.
Our commercial approach is shifting from selling individual products to offering our broad portfolio to customers with integrated solutions that can support entire unit operations, the management of fluids between unit operations, and in-line advanced analytics.
Our Franchises Products Filtration : Filtration is our largest franchise with the broadest product offering covering upstream and downstream technologies.
Our XCell ATF (Alternating Tangential Flow) systems are used in upstream bioprocessing for perfusion applications including seed train intensification (N-1), production bioreactor (N), intensified fed-batch, and continuous manufacturing to improve volumetric productivity.
REMOVED
10-K Summary 62 SIGNATURES 63 Summary of the Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business.
Investors are cautioned that express or implied statements in this Form 10-K that are not strictly historical statements, including, without limitation, statements regarding current or future financial performance, potential impairment of future earnings, management s strategy, plans and objectives for future operations or acquisitions, product development and sales, research and development, selling, general and administrative expenditures, intellectual property and adequacy of capital resources and financing plans constitute forward-looking statements.
We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs including monoclonal antibodies ( mAbs ) and mAb derivatives, recombinant proteins, RNA-based therapeutics and vaccines, and cell and gene therapies ( C GT ) that are improving human health worldwide.
Increasingly, our technologies are being implemented to overcome challenges in processing plasmid DNA (a starting material for the production of mRNA) and gene delivery vectors such as lentivirus and adeno-associated viral vectors.
A majority of our 16 manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey, and New York).
2 The majority of our revenue is derived from consumable and/or single-campaign ( single-use ) product sales, as compared to associated hardware and equipment.
Shifting to Integrated Solutions Since 2012, and through year end 2024, we have completed 14 acquisitions across our four franchises, building a base of technology assets that we can improve upon and/or develop next-generation versions of through our internal R D team.
Our acquisition strategy is purposeful, considering the potential for integration with our internally-developed technologies, and across products and franchises.
In 2024, the results of our mergers and acquisitions and R D efforts are reflected in our ability to offer more integrated solutions across the bioproduction workflow.
Our commercial approach is shifting from individual product to whole system sales that can support entire unit operations, the management of fluids between unit operations, and in-line advanced analytics.